Women's Interest in Chemoprevention for Breast Cancer

Open Access

9 July 2001

journal article
research article
Published by American Medical Association (AMA) in Archives of internal medicine (1960)

Vol. 161 (13) , 1639-1644
https://doi.org/10.1001/archinte.161.13.1639

Abstract

CHEMOPREVENTION is the use of pharmacologic or natural agents to inhibit the development of cancer. Currently, tamoxifen citrate is the only approved chemopreventive agent for breast cancer.¹ Decision making about chemoprevention for breast cancer is difficult and should require, at minimum, identification of potential risks and benefits based on a woman's profile of breast cancer risk factors.

This publication has 16 references indexed in Scilit:

A 40-Year-Old Woman With a Strong Family History of Breast Cancer
JAMA, 1999
Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer
JNCI Journal of the National Cancer Institute, 1999
Decision aids for patients facing health treatment or screening decisions: systematic review
BMJ, 1999
Confusion about Mammography: Prevalence and Consequences
Journal of Women's Health & Gender-Based Medicine, 1999
Decision Aids for Patients Considering Options Affecting Cancer Outcomes: Evidence of Efficacy and Policy Implications
JNCI Monographs, 1999
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
JNCI Journal of the National Cancer Institute, 1998
Perceptions of Breast Cancer Risk and Screening Effectiveness in Women Younger Than 50 Years of Age
JNCI Journal of the National Cancer Institute, 1995
Screening for Depression in Well Older Adults: Evaluation of a Short Form of the CES-D
American Journal of Preventive Medicine, 1994
Clinical management of women at increased risk for breast cancer
Breast Cancer Research and Treatment, 1993
Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually
JNCI Journal of the National Cancer Institute, 1989